Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

Kami J. Maddocks, MD, Jonathon B. Cohen, MD, Ying Huang, MA, MS, Beth A Christian, MD, Don M Benson, MD PhD, Jeffrey Jones, MD MPH, Christopher Flowers, MD MS, Leonard T. Heffner, MD, Cynthia Jenkins, RN, Jennfer Sexton, MHA, CCRC, Alison Neal, MPH, Melissa Kives, MPH, Kristie A. Blum, MD

Blood (2016) 128 (22): 1776.

https://doi.org/10.1182/blood.V128.22.1776.1776

Published: 2016

Journal Articles

Combination Therapy with Daratumumab and CAR-NK Targeting CS1 for Multiple Myeloma

Yibo Zhang, PhD, Lichao Chen, Yufeng Wang, Xinxin Li, Tiffany Hughes, Hans Klingemann, Don M Benson, MD PhD, Jianhua Yu, PhD

Blood (2016) 128 (22): 1342.

https://doi.org/10.1182/blood.V128.22.1342.1342

Published: 2016

Journal Articles

Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation

Daniel R Richardson, MD, Ying Huang, MA, MS, Patrick Elder, MS, Joanna Newlin, LISW, Cyndi Kirkendall, LISW, Steven M Devine, MD, Leslie A. Andritsos, MD, Don M Benson, MD PhD, William Blum, MD, Yvonne A Efebera, MD MPH, Craig C Hofmeister, Samantha Jaglowski, MD MPH, Rebecca B Klisovic, MD, Heather L McGinty, PhD, Sam Penza, MD, Sumithra Vasu, MBBS, Basem M William, MD, Ashley E Rosko, MD

Blood (2016) 128 (22): 1241.

https://doi.org/10.1182/blood.V128.22.1241.1241

Published: 2016

Journal Articles

Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation

Blood (2016) 128 (22): 3409.

https://doi.org/10.1182/blood.V128.22.3409.3409

Published: 2016

Journal Articles

Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation

Blood (2016) 128 (22): 3410.

https://doi.org/10.1182/blood.V128.22.3410.3410

Published: 2016

Journal Articles

Anti-Depressant Use in Patients with Multiple Myeloma Less Common Than Expected

Hui Hui Li, MD, Nita Williams, Nidhi Sharma, PhD, Yvonne A Efebera, MD MPH, Ashley E Rosko, MD, Don M Benson, MD PhD, Craig C Hofmeister

Blood (2016) 128 (22): 2420.

https://doi.org/10.1182/blood.V128.22.2420.2420

Published: 2016

Journal Articles

Doses of Total Nucleated Cells and Activated T-Cells Transplanted Influence Survival and Graft Versus Host Disease Among AML and MDS Recipients of Reduced-Intensity Mobilized Peripheral Blood Allografts

Daniel R Richardson, MD, Qiuhong Zhao, MS, Rhonda Kitzler, MS, Patrick Elder, MS, Gerard Lozanski, MD, Leslie A. Andritsos, MD, Don M Benson, MD PhD, William Blum, MD, Yvonne A Efebera, MD MPH, Samantha Jaglowski, MD MPH, Rebecca B Klisovic, MD, Sam Penza, MD, Sumithra Vasu, MBBS, Steven M Devine, MD

Blood (2016) 128 (22): 4598.

https://doi.org/10.1182/blood.V128.22.4598.4598

Published: 2016

Journal Articles

Relative Clone Size By FISH of Both Del(13q) and Del(17p) Independently Impact Overall Survival

Soluman Culver, MD MS, Nita Williams, Nidhi Sharma, PhD, Yvonne A Efebera, MD MPH, Ashley E Rosko, MD, Don M Benson, MD PhD, Craig C Hofmeister

Blood (2016) 128 (22): 4444.

https://doi.org/10.1182/blood.V128.22.4444.4444

Published: 2016

Journal Articles

Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)

Hassan Issa, MD, Amy S. Ruppert, MAS, Patrick Elder, M.S, Craig Hofmeister, Don M Benson, MD PhD, Sam Penza, MD, Leslie A. Andritsos, MD, Rebecca B. Klisovic, MD, Sumithira Vasu, MBBS, William Blum, MD, Samantha M. Jaglowski, MD, Steven M. Devine, MD, Yvonne A Efebera, MD

Blood (2015) 126 (23): 4328.

https://doi.org/10.1182/blood.V126.23.4328.4328

Published: 2015

Journal Articles

Reolysin Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients

Douglas W Sborov, MD MS, Flavia Pichiorri, PhD MSC, Gerard J Nuovo, MD, Don M Benson, MD PhD, Yvonne A. Efebera, MD MPH, Ashley E Rosko, MD, Craig C Hofmeister, MD MPH

Blood (2015) 126 (23): 1835.

https://doi.org/10.1182/blood.V126.23.1835.1835

Published: 2015

Journal Articles

First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma

Yvonne A. Efebera, MD MPH, Ashley E Rosko, MD, Craig Hofmeister, Joe Benner, BS, Courtney Bakan, BS, Kathleen Stamper, BS, Tammy Lamb, CNP, Devine Hollie, CNP, Megan Sell, CNP, David Avigan, MD, Don M Benson, MD PhD

Blood (2015) 126 (23): 1838.

https://doi.org/10.1182/blood.V126.23.1838.1838

Published: 2015

Journal Articles

Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers

David Ciarlariello, Sean Harshman, Alessandro Canella, Erinn Hade, Alberto Rocci, MD, Antonio Palumbo, MD, Craig C Hofmeister, MD MPH, Michael Freitas, Don M Benson, MD PhD, Flavia Pichiorri, PhD

Blood (2015) 126 (23): 1814.

https://doi.org/10.1182/blood.V126.23.1814.1814

Published: 2015

Journal Articles

Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients

Ashley E Rosko, MD, Craig C Hofmeister, MD MPH, Yvonne A Efebera, MD, Don M Benson, MD PhD, Douglas W Sborov, MD MS, Samantha Jaglowski, MD MPH, Steve Devine, MD, Tanya M Wildes, MD MSCI, James Gillahan, Desiree Jones, Ying Huang, MA, MS, Christin E Burd, PhD

Blood (2015) 126 (23): 3200.

https://doi.org/10.1182/blood.V126.23.3200.3200

Published: 2015

Journal Articles

A Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NHL)

Kami J. Maddocks, MD, Jonathon B. Cohen, MD, Beth A Christian, MD, Don M Benson, MD PhD, Kristie A. Blum, MD

Blood (2015) 126 (23): 5114.

https://doi.org/10.1182/blood.V126.23.5114.5114

Published: 2015

Journal Articles

HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide

Hector Cordero-Nieves, BS, Douglas W. Sborov, MD, Alessandro Canella, MS, Zhongfa Liu, Jessica Consiglio, MS, Wenjun Ni, Emily Smith, Lara Rizzotto, PhD, Yvonne A Efebera, MD, Don M. Benson, MD PhD, Luciano Cascione, Mo Xiaokui, MS, John C. Byrd, MD, Michael R. Grever, MD, Craig C Hofmeister, MD MPH, Flavia Pichiorri, PhD

Blood (2014) 124 (21): 3377.

https://doi.org/10.1182/blood.V124.21.3377.3377

Published: 2014

Journal Articles

Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation

Sumithira Vasu, MBBS, Anissa Bingman, M.S., Susan Geyer, PhD, Patrick Elder, Rhonda Kitzler, BS, Hillary Bradbury, Lynn Odonnell, William Blum, MD, Samantha M. Jaglowski, MD MPH, Leslie A. Andritsos, MD, Rebecca B. Klisovic, MD, Sam Penza, MD, Yvonne A Efebera, MD, Craig C. Hofmeister, MD, Don M. Benson, MD PhD, Natarajan Muthusamy, DVM, PhD, Gerard Lozanski, MD, Steven M. Devine, MD

Blood (2014) 124 (21): 2494.

https://doi.org/10.1182/blood.V124.21.2494.2494

Published: 2014

Journal Articles

A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Thomas G. Martin, MD, Rachid Baz, MD, Don M. Benson, MD PhD, Nikoletta Lendvai, MD PhD, Frank Campana, MD, Eric Charpentier, Ravi Vij, MBBS, MD

Blood (2014) 124 (21): 83.

https://doi.org/10.1182/blood.V124.21.83.83

Published: 2014

Journal Articles

Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT)

Yvonne A Efebera, MD, Susan Geyer, PhD, Anissa Bingman, M.S., Patrick Elder, MS, Rhonda Kitzler, BS, Kevin Coombes, PhD, Carrie Hennelly, MA, Katie Cortright, BS, Leslie A. Andritsos, MD, Samantha M. Jaglowski, MD MPH, Sumithira Vasu, MBBS, William Blum, MD, Rebecca B. Klisovic, MD, Sam Penza, MD, Craig C Hofmeister, MD MPH, Don M Benson, MD PhD, Gerard Lozanski, MD, Steven M. Devine, MD

Blood (2014) 124 (21): 3929.

https://doi.org/10.1182/blood.V124.21.3929.3929

Published: 2014

Journal Articles

Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies.

Ian W Flinn, M.D., Ph.D., John C. Byrd, M.D., Richard R Furman, MD, Jennifer R Brown, MD, PhD, Don M Benson, MD, PhD, Steven E Coutre, MD, Brad S Kahl, M.D., B. Douglas Smith, M.D., Nina D. Wagner-Johnston, MD, Stephen E Spurgeon, MD, Neill A. Giese, Ph.D., Albert S Yu, MD

Blood (2009) 114 (22): 922.

https://doi.org/10.1182/blood.V114.22.922.922

Published: 2009

Journal Articles

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Patients with Multiple Myeloma.

Mehdi Hamadani, MD, Erinn M. Hade, MS, Patrick Elder, Don M. Benson, MD PhD, Craig C. Hofmeister, MD

Blood (2007) 110 (11): 5129.

https://doi.org/10.1182/blood.V110.11.5129.5129

Published: 2007

NARROW

a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

Combination Therapy with Daratumumab and CAR-NK Targeting CS1 for Multiple Myeloma

Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation

Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation

Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation

Anti-Depressant Use in Patients with Multiple Myeloma Less Common Than Expected

Doses of Total Nucleated Cells and Activated T-Cells Transplanted Influence Survival and Graft Versus Host Disease Among AML and MDS Recipients of Reduced-Intensity Mobilized Peripheral Blood Allografts

Relative Clone Size By FISH of Both Del(13q) and Del(17p) Independently Impact Overall Survival

Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)

Reolysin Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients

First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma

Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers

Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients

A Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NHL)

HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide

Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation

A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT)

Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies.

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only